Clinical trial
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic…
NCT00019396 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019396 |
|---|---|
| Title | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer |
| Official title | Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma |
| Intervention type | Drug |
| Interventions | flt3 ligand, gp100 antigen, MART-1 antigen, Montanide ISA-51, tyrosinase peptide |
| Start date | Feb 1, 1998 |
| Completion | Mar 1, 2007 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: